# AstraZeneca plc -11.1% potential downside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-11-1-potential-downside-indicated-by-deutsche/4121163324
- Published: 2024-07-01T13:38:29+01:00
- Author: Charlotte Edwards

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**
with ticker ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
now has a potential downside of -11.1% according to Deutsche.
AZN.LDeutsche set 
a target price of 11,000 GBX for the company, which when compared to the AstraZeneca
plc share price of 12,368 GBX at opening today (01/07/2024) indicates a potential
downside of -11.1%. Trading has ranged between 9,461 (52 week low) and 12,704 (52
week high) with an average of 1,995,179 shares exchanging hands daily. The market
capitalisation at the time of writing is £190,465,933,020.AstraZeneca PLC is a science-
led biopharmaceutical company. The Company is focused on the discovery, development,
and commercialization of prescription medicines in oncology, rare diseases, and 
biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory 
and immunology and vaccines and immune therapies. Its key marketed oncology products
include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex
and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and 
Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others.
It offers investigational vaccine candidate IVX-A12, which targets both respiratory
syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265
targeting prostate specific membrane antigen for metastatic castration resistant
prostate cancer, which is in a Phase II trial. It is also focused on discovering,
developing, and manufacturing of T-cell receptor therapies.

Share on: